OSE IMMUNOTHERAPEUTICS (FR0012127173) — research page

FR · fr-cm-kg/XPAR/FR0012127173 · as of 2026-11-06

Identity and listing

The issuer is OSE IMMUNOTHERAPEUTICS, listed on Euronext Paris, with ticker FR0012127173 and ISIN FR0012127173, and LEI 969500HIUWVGY6NZSM05. Its security type is Corporate, its segment is not on the record, its sector is NAF 72.11Z, and its jurisdiction is France (RCS-registered SA à conseil d'administration (s.a.i.)). Its listing status is listed, not halted.

field	value	source · read date
name	OSE IMMUNOTHERAPEUTICS	source · 2026-11-06
exchange	Euronext Paris	source · 2026-11-06
ticker	FR0012127173	source · 2026-11-06
ISIN	FR0012127173	source · 2026-11-06
LEI	969500HIUWVGY6NZSM05	source · 2026-11-09
security type	Corporate	source · 2026-11-06
segment	not on the record
sector	NAF 72.11Z	source · 2026-11-06
jurisdiction	France (RCS-registered SA à conseil d'administration (s.a.i.))	source · 2026-11-06
status	listed, not halted	source · 2026-11-09

The disclosure read

The record holds 25 filings in the window 2025-11-06 to 2026-11-06, across 19 filing days. The median gap between filing days is 6.0 days. The latest filing is dated 2026-11-02, is of type regulatory filing, and falls 4 days before the record date of 2026-11-06. Exchange peers on Euronext Paris number 316, with a median of 15.0 filings, a median cadence gap of 8.0 days and a median latency of 3 days. Sector peers on NAF 72.11Z number 24, with a median of 20.0 filings, a median cadence gap of 8.5 days and a median latency of 2.0 days.

	filings	median gap between filing days	days from latest filing to as-of
this issuer	25	6	4
exchange median: Euronext Paris (316 issuers)	15	8	3
sector median: NAF 72.11Z (24 issuers)	20	8.5	2

date	type	category	filing
2026-11-02	regulatory_filing	VAD	DeclarationPositionsCourtes [VAD]
2026-10-29	newswire_release		OSE Immunotherapeutics annonce des résultats positifs
2026-10-29	newswire_release		OSE Immunotherapeutics Reports Additional Positive Results
2026-10-28	regulatory_filing	VAD	DeclarationPositionsCourtes [VAD]
2026-10-23	regulatory_filing	VAD	DeclarationPositionsCourtes [VAD]

window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is not on the record. The record carries the annual report link only, and that link is a source reference, not a read. The auditor's location is not on the record, and auditor changes are not on the record because no lifecycle type map exists for this register yet.

Events and halts

Listing, delisting, name change, domicile change and segment move are each not on the record, because no lifecycle type map exists for this register yet. The halt flag is listed, not halted.

Orderability

The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/fr/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.

rule acm-68000/fr/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

No research houses were found on the issuer's own investor-relations pages read, and the count is 0.

Open research

The record holds 10 openly published research notes, all by Edison Investment Research, dated 2026-03-03, 2025-10-20, 2025-08-29, 2025-06-05, 2025-05-22, 2023-12-12, 2023-07-05, 2023-05-24, 2023-03-01 and 2019-09-30.

date	publisher	note	kind
2026-03-03	Edison Investment Research	OSE Immunotherapeutics \| Reaffirmed dedication to core assets	issuer-sponsored
2025-10-20	Edison Investment Research	OSE Immunotherapeutics \| Refocusing for the next phase	issuer-sponsored
2025-08-29	Edison Investment Research	OSE Immunotherapeutics \| Spotlight on OSE's diverse clinical pipeline	issuer-sponsored
2025-06-05	Edison Investment Research	OSE Immunotherapeutics \| New UC biomarker underpins growth strategy	issuer-sponsored
2025-05-22	Edison Investment Research	OSE Immunotherapeutics \| Strategic collaboration in mRNA technologies	issuer-sponsored
2023-12-12	Edison Investment Research	OSE Immunotherapeutics \| FIRsT interim data provides validation	issuer-sponsored
2023-07-05	Edison Investment Research	OSE Immunotherapeutics \| Update	issuer-sponsored
2023-05-24	Edison Investment Research	OSE Immunotherapeutics \| Re-initiation of coverage: Milestones anticipated throughout FY23	issuer-sponsored
2023-03-01	Edison Investment Research	OSE Immunotherapeutics \| Update	issuer-sponsored
2019-09-30	Edison Investment Research	OSE Immunotherapeutics \| R&D progress triggers milestone payment windfall	issuer-sponsored

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

licensor	entitlement	title	date	source
none loaded

As-of depth

The vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.

Sources

17 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1: https://registers.esma.europa.eu/publication/searchRegister?core=esma_registers_firds (identity.exchange)
10.2: https://recherche-entreprises.api.gouv.fr/search?q=479457715 (identity.jurisdiction)
10.3: https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
10.4: https://mcp.fr-cm-kg.ai/events/XPAR/FR0012127173 (the disclosure lines)
10.5: https://live.euronext.com/en/ajax/haltedInstrument/getAjax/current (the halt flag)
10.6: https://mcp.fr-cm-kg.ai/book/aio.json (the orderability chapter)
10.7: https://www.ose-immuno.com/wp-content/uploads/2026/03/Edison-Securities_030326.pdf (open research)
10.8: https://www.ose-immuno.com/wp-content/uploads/2025/10/Edison-20-October-2025.pdf (open research)
10.9: https://www.ose-immuno.com/wp-content/uploads/2025/08/Edison_290825.pdf (open research)
10.10: https://www.ose-immuno.com/wp-content/uploads/2025/06/Edison_050625.pdf (open research)
10.11: https://www.ose-immuno.com/wp-content/uploads/2025/05/Edison_22-mai-2025.pdf (open research)
10.12: https://www.ose-immuno.com/wp-content/uploads/2023/12/Edison-note-121223.pdf (open research)
10.13: https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-050723.pdf (open research)
10.14: https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-240523-1.pdf (open research)
10.15: https://www.ose-immuno.com/wp-content/uploads/2023/09/Edison-010323.pdf (open research)
10.16: https://www.ose-immuno.com/wp-content/uploads/2021/10/OSE-Immunotherapeutics-RD-progress-triggers-milestone-payment-windfall_30-Sept-19.pdf (open research)
10.17: https://mcp.fr-cm-kg.ai/record/XPAR/FR0012127173 (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"FR0012127173"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:7c9999435afec821.